**Gynecology**

**OVARIAN (or FALLOPIAN, PERITONEAL) CANCER**

- **First-line/Maintenance**
  - **No current studies**

- **Recurrent, Platinum-Sensitive**
  - **eIRB# 19908**
    - A Phase 1/2 Galinpepimut-S in combination with Pembrolizumab

- **Recurrent, Platinum-Resistant**
  - **eIRB# 20016**
    - TESARO MOONSTONE/GOG 3032: Combination of niraparib (PARP-inhibitor) and TSR-042 (PD-1 inhibitor) in platinum-resistant ovarian cancer

**CERVICAL CANCER**

- **eIRB# 20897**
  - CERVICAL-17: Bintrafusp alfa (M7824) monotherapy in advanced, unresectable cervical cancer

- **eIRB# 21007**
  - Wee-1 inhibition prior to primary surgery for newly diagnosed ovarian cancer

**ENDOMETRIAL (UTERINE) CANCER**

- **eIRB# 16716**
  - Closed to enrollment

- **eIRB# 21271**
  - DUO-E/GOG 3041: First-line chemotherapy with durvalumab followed by maintenance durvalumab with or without olaparib in newly diagnosed or recurrent endometrial cancer

**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

06/01/2020